Program
HSK42360
A development code. Also written as “HSK42360-Na Tablets” and “HSK42360-Na”.
Its studies are mostly in Colorectal Neoplasms · Brain Neoplasms, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 44 open or running | phase 2since Aug 13, 2026 | Jul 24, 2024 | Dec 2, 2028phase 1 · NCT07561554 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 24, 2024First study: phase 1 study in Solid TumorsFirst studyNCT06536400 · 316 planned · China
- Aug 6, 2025Phase 1 study in Malignant Brain TumorsNCT07158710 · 159 planned · China
- Mar 23, 2026Phase 1 study in Solid Tumors (Phase 1)NCT07561554 · 159 planned · China
- Aug 13, 2026Phase 2 study in Colorectal NeoplasmsPhase 2 reachedNCT07790510 · 180 planned · China
Ahead
- Dec 2, 2028Primary completion: phase 1 study in Solid Tumors (Phase 1)NCT07561554
- May 23, 2029Primary completion: phase 1 study in Malignant Brain TumorsNCT07158710
- Sep 30, 2029Primary completion: phase 2 study in Colorectal NeoplasmsNCT07790510
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07790510Colorectal Neoplasms · China | 2 | Recruiting | Sep 30, 2029 | 180 |
| NCT07561554Solid Tumors (Phase 1) · China | 1 | Recruiting | Dec 2, 2028 | 159 |
| NCT07158710Malignant Brain Tumors · China | 1 | Recruiting | May 23, 2029 | 159 |
| NCT06536400Solid Tumors · China | 1 | Recruiting | Aug 30, 2026 | 316 |
How it is read
Names in the registry
- “HSK42360”, 2 entries
- “HSK42360-Na Tablets”, 1 entry
- “HSK42360-Na”, 1 entry
Codes read as this program: HSK42360.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Brain Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.